Â鶹´«Ã½¸ßÇå

HTC News Archives

News Articles and Links Previously Featured on our Site

• 11/15/2024 Potential Hemophilia Treatment SerpinPC Halted by Centessa
• 11/8/24 Study Finds Missing Clotting Proteins in Hemophilia Patients Can Directly Affect Bone Health
• 10/18/24 Study Shows Sevenfact Safe, Effective for Patient with Hemophilia A or B with Inhibitors
• 10/11/24 FDA Approves First Non-Factor, Once-Weekly Treatment for Hemophilia A or B
• 10/1/24 Study Suggests Hemlibra Effectively Prevents Bleeding in Acquired Hemophilia A
• 9/13/24 Survey Finds Most Men With Hemophilia Continue to Have Joint Problems Even With Prophylaxis
• 9/6/24 Gene Editing Therapy Shows Promise in Pre-Clinical Study in Animals
• 8/20/24 Gene Therapy Data for Roctavian Shows Most Remained Off Preventative Therapy after Seven Years
• 8/6/24 Prophylactic Treatment of Hemophilia Linked to Less Disability-related Unemployment
• 8/1/24 Pfizer Shares Positive Trial Data for Hemophilia A Gene Therapy
• 7/16/24 Small Study Shows Extended Half-life Using Experimental Treatment for Hemophilia with Inhibitors
• 6/14/24 Study Shows Hemlibra Safe, Effective in Older Patients
• 6/7/24 FDA Grants Orphan Drug Status to Biopharma's Treatment for Hemophilia B
• 5/22/24 Phase 3 Trial Shows Mim8 Better at Reducing Bleeds for Hemophilia A Patients than Standard Treatments
• 5/15/24 New Study Shows Long Term Benefits of Gene Therapy for Severe Hemophilia A
• 4/30/24 FDA Approves New Hemophilia B Gene Therapy Product BEQVEZ
• 4/16/24 New Long-Term Data Shows Emicizumab Safe, Effective in Hemophilia A Patients
• 4/12/24 Study Shows Wristband Tracking Activity Improves Quality of Life in Severe Hemophilia Patients
• 3/26/24 FDA Approves IXINITY for Use in Children 12 and Under with Hemophilia B
• 3/15/24 ReciBioPharm Teams Up with GeneVentiv to Develop Gene Therapy for All Hemophilia Patients
• 2/28/24 FDA Approves First Human Study of CRISPR/Cas9-based Factor 9 Gene Editing Therapy
• 2/23/24 Muscle Loss Common in Hemophilia A Patients with Joint Bleeds
• 2/7/24 Trial Shows Roctavian, Gene Therapy, Maintains Effectiveness after Seven Years
• 1/31/24 NBDF Names Phil Gattone, M.Ed as Next CEO
• 1/17/24 Jivi Safe, Effective for Hemophilia A in Long-term Study
• 1/12/24 First US Patient Treated with Hemophilia A Gene Therapy Outside Clinical Trial
• 12/22/23 Three Year Study Shows SerpinPC is Safe and Reduces Bleeds in Hemophilia A & B
• 12/20/23 Hemgenix Lowers Bleeding Rates and the Rate of Replacement Therapy
• 12/6/23 Dosing Begins in Phase 1/2a Trial of Optimized Gene Therapy for Hemophilia A  
• 11/29/23 FDA Grants Dual Designations for Investigational Hemophilia A Therapy
• 11/10/23 Novo Nordisk and Genevant Join Forces to Develop Gene-editing Treatment for Hemophilia A
• 11/6/23 Study Looks at Therapeutic Options for Women with VWD and Heavy Menstrual Bleeding
• 10/13/23 Over Half of Hemophilia Patients Hide Symptoms and Avoid Sharing Negative Impacts
• 10/11/23 Study Shows Hemophilia Survival Rate Disparities
• 9/29/23 FDA Grants Orphan Drug Status to Baudax Bio's TI-168 for Hemophilia A with Inhibitors
• 9/8/23 Â鶹´«Ã½¸ßÇå Man Shares Positive Results from Gene Therapy Treatment
• 9/6/23 Analysis Shows Preventative Treatment with Extended Half-Life Products Improves Outcomes
• 8/17/23 NHF Changes Name to NBDF to Include All Bleeding Disorders
• 8/9/23 Small Number of Young Patients Experience Severe Bleeds on Hemlibra
• 8/2/23 Gene Therapy Roctavian Likely to Arrive in US in August 2023
• 7/28/23 Roche's Gene Therapy Trial of SPK-8011 Moves Forward to Phase 3
• 7/20/23 Recent Studies Show Fitusiran Could Treat Women's Bleeding Disorders
• 7/19/23 In Non-Severe Hemophilia A, Hemlibra is not as Cost-Effective as Standard Care
• 6/29/23 FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
• 6/16/23 FDA Will Review Ixinity for Use in Children Under 12 with Hemophilia B
• 6/9/23 Early Prophylaxis Leads to Better Outcomes for Hemophilia A Patients
• 5/31/23 Pfizer Announces Positive Results from Phase 3 BASIS Study of Marstacimab
• 5/10/23 Study Shows Female Hemophilia A Patients and Carriers Undertreated
• 5/5/23 AstraZeneca, Sernova Join Forces on Cell Therapy Research
• 5/4/23 FDA Asks for More Information on Concizumab from Novo Nordisk
• 4/12/23 Survey of HTC Clinicians Shows Changes in Treatment Trends over 22 Years
• 4/6/23 Sanofi Announces Results from Two Phase 3 Trials of Fitusiran
• 3/15/23 Dr. Beth Warren Discusses Differences in Factor and Non-factor Prophylaxis in ASH Publication
• 3/15/23 New Data:  Hemgenix Reduces Bleeds in Hemophilia B Better than Standard Therapy
• 3/8/23 FDA Extends Review of Gene Therapy Roctavian for Hemophilia A
• 2/24/23 FDA Approves Efanesoctocog alfa (Altuviiio) to Treat Hemophilia A
• 2/13/23 Emicizumab (Hemlibra) Appears Safe, Effective in Mild or Moderate Hemophilia
• 2/6/23 Study Shows Efanesoctocog Alfa Prophylaxis Effective in Hemophilia A
• 2/2/23 Changes Coming to State Medicaid and CHIP Programs
• 1/13/23 Roctavian Trial Update Shows Most Patients Bleed Free at Three Years
• 1/11/23 FDA Clears Test to Monitor Effectiveness of Hemophilia B Treatments
• 1/4/23 Pfizer Announces Updates for Investigational Gene Therapy for Hemophilia A
• 12/16/22 Data Shows SerpinPC Reduces Bleeds for All Hemophilia Types
• 12/12/22 Phase 1/2 Study Shows Durability of Investigational Gene Therapy SPK-8011 in Patient with Hemophilia A
• 11/22/22 FDA Approves First Gene Therapy for Hemophilia B
• 11/08/22 BioMarin Faces Possible Delay for Hemophilia A Gene Therapy
• 11/2/22 Study Shows Heart Risk Higher in Less Active Adult Hemophilia Patients
• 10/26/22 Real World Study Shows Switch to Kovaltry Safe, Effective for Hemophilia A
• 9/30/22 BioMarin Resubmits Hemophilia A Gene Therapy for FDA Approval
• 9/30/22 Research Shows Untreated Hemophilia A Bleeds are Common
• 9/23/22 Pfizer and Sangamo Gene Therapy Phase 3 Trial to Resume After Pause for Safety Concerns
• 9/16/22 FDA Grants Orphan Drug Status to SerpinPC for Hemophilia B
• 8/31/22 FDA Grants Priority Review of Efanesoctocog Alfa for Hemophilia A
• 8/19/22 Hemlibra Improves Joint Health in Younger Hemophilia A Patients in Trial
• 8/4/22 Recombinant von Willebrand Factor prophylaxis May Reduce ABR in Patients with VWD
• 8/1/22 FDA Approves Rebinyn for Routine Prophylaxis in Patients with Hemophilia B
• 7/18/22 Freeline Shares Positive Data from Gene Therapy Trial
• 7/10/22 Sanofi Shares Data from Two Phase 3 Studies
• 7/8/22 NHF Requests Evaluation and Mitigation Study for Pending Gene Therapies
• 6/10/22 Elocta (Eloctate in the US) Reduced Elbow, Knee Bleeds in Severe Hemophilia A
• 6/2/22 Bayer Announces Discontinuation of Kogenate FS
• 6/1/22 FDA Grants Breakthrough Status to efanesoctocog alfa (BIVV001) for Hemophilia A
• 5/9/22 Emicizumab Safe, Effective in Hemophilia A Patients with Inhibitors
• 5/9/22 Arthritis Medicine Helps Prevent FVIII Inhibitors in Animal Study
• 5/3/22 FDA Clears Pfizer to Resume Hemophilia Gene Therapy Trial
• 4/29/22 Research Shows Eptacog Beta Safe and Effective in Pediatric Patients  
• 4/20/22 Bone Disorders More Common for Female Hemophilia Carriers and VWD Patients
• 4/13/22 Rebinyn Shows Positive Data in Canadian Real World Study
• 3/25/22 First US Patient Dosed in Freeline's Hemophilia B Gene Therapy Trial
• 3/21/22 Gene Therapy Roctavian Safely Raises FVIII Levels for Hemophilia A Patients in Trial
• 3/9/22 Sobi and Sanofi Announce Positive Data for Efanesoctocog Alfa to Treat Hemophilia A
• 3/2/22 Joint Damage Still Evident in Hemophilia A Patients with Milder Disease
• 2/14/22 Vibrating Microbubbles May Improve Gene Therapy Delivery for Hemophilia A
• 2/7/22 The Legacy of HTCs: Article from HFA's Dateline Federation-see page 20
• 2/2/22 Bleeds, Physical Limitations, Affect Severe Hemophilia A Patients Despites Prophylaxis
• 1/14/22 Study Shows Low Dose ITI Partially Successful in 80% of Children with Hemophilia A
• 1/10/22 BioMarin Announces Positive Results in Gene Therapy Study for Hemophilia A
• 12/31/21 NHF Mournes the Loss of Longtime CEO and Advocate, Val Bias
• 12/9/21 Update for Hemophilia B Gene Therapy Trial from uniQure and CSL Behring
• 12/1/21 Hemophilia A Patient Develops Complications in SIG-001 Clinical Trial
• 11/23/21 Data Analysis Sheds Light on Bleeding Patterns of Young VWD Patients
• 11/15/21 Data Finds Fitusiran Reduced Bleeds in Patients with Hemophilia A and B
• 11/10/21 FDA Puts Hold on Gene Therapy SB-525 Phase 3 Trial
• 11/5/21 Small Study Finds Extended FIX Prophylactic Therapy May Not Ease Pain
• 10/18/21 Long-Term Preventative Use of Esperoct Effective in Hemophilia A
• 10/11/21 "Reverse Vaccination" May Help Prevent Immune Response
• 9/29/21 Study Finds Breakthrough Bleeds Likely for Hemophilia A Patients on Hemlibra
• 9/15/21 FDA Restores BeneFIX as Prophylactic for Children with Hemophilia B
• 9/13/21 SerpinPC Prevents Bleeds in Hemophilia A and B Patients in Phase 2a Trial
• 9/7/21 NHF and HFA Partner to Create "Together Project"
• 8/6/21 Emicizumab (Hemlibra) May Improve Outcomes for Acquired Hemophilia A
• 8/4/21 Phase 2 Study Shows Monoclonal Antibody Marstacimab Appears Safe and Effective
• 8/2/21 Spark Therapeutics Shares Update for Gene Therapy SPK-8011 Trial
• 7/19/21 New Data for BioMarin's Gene Therapy for Hemophilia A Shared at ISTH
• 7/9/21 FDA Puts Hold on Sigilon's Hemophilia Cell Therapy Trial
• 7/9/21 ASC Therapeutics to Begin Phase 1/2 Gene Therapy Clinical Trial for Hemophilia A
• 6/18/21 Study Analyzes Risk of Inhibitors in Non-Severe Hemophlia A
• 6/14/21 Prophylactic Hemlibra May Lower Treatment Costs for Hemophilia A Patients
• 6/9/21 Book Contest for Hemophilia B Patients Ends June 30
• 5/25/21 Gene Therapy Trial Data Suggest Efficacy in the Presence of Antibodies
• 5/19/21 Roctavian, Gene Therapy for Hemophilia A, Shows Potential from Early Data
• 5/18/21 First Patient Dosed in Marzeptacog Alfa (MarzAA) Phase 1/2 Study
• 5/7/21 Jivi May Prevent Bleeds in Minor Surgery for Hemophilia A Patients
• 4/16/21 Dosing Begins for Efanesoctocog Alfa Trial in Boys with Hemophilia A
• 4/14/21 Graphic Novel Shares Life with Hemophilia, Dungeons and Dragons
• 4/12/21 Jivi Continues to Prevent Bleeds in Severe Hemophilia A Long-term
• 4/07/21 Study Shows Continuous Advate IV Effectively Prevented Bleeds in Surgery
• 3/31/21 Investigation Shows that Gene Therapy AMT-061 Unlikely to Have Caused Liver Tumor
• 3/12/21 Genentech Updates Hemlibra Labeling
• 3/10/21 BioMarin's Roctavian, Gene Therapy for Hemophilia A, Gets FDA Regenerative Medicine Advanced Therapy Status
• 2/24/21 Nuwiq Shows a Low Risk of Developing Inhibitors in Hemophilia A Trial
• 2/19/21 FDA puts Efanesoctocog Alfa on Fast Track Designation to treat Hemophilia A
• 2/17/21 Recent Study Shows Hemlibra Can Help Manage Acquired Hemophilia A
• 1/29/21 Study Shows Esperoct Highly Effective as Prophylaxis Treatment for Hemophilia A
• 1/25/21 BioMarin Shares Positive Phase 3 Data for valactocogene roxaparvovec, Gene Therapy for Hemophilia A
• 1/21/21 CSL Behring Issues Voluntary Recall of Mononine
• 1/18/21 Study Suggests Eloctate Induces Faster immune Tolerance than other Regimens
• 1/13/21 Phase 3 Trial Shows Sustained Drop in Bleeding Rates for Roctavian, Gene Therapy for Hemophilia A
• 12/29/20 NHF Shares Information about COVID-19 Vaccines
• 12/20/20 FDA Puts Clinical Hold on uniQure's Hope B Trial
• 12/8/20 Updated Phase 1/2 Gene Therapy Study Data Presented at ASH
• 12/7/20 MarzAA for Hemophilia A or B with Inhibitors Given Fast Track Status from FDA
• 11/20/20 UniQure Shares positive Data from AMT-061 Gene Therapy Trial for Hemophilia B
• 11/11/20 Study Finds Passive Stretching, Manual Therapy Helps Joints of Hemophilia Patients
• 11/3/20 Results Published from Patient Satisfaction Survey Show Positive Reviews of HTCs Nationwide
• 10/26/20 Data Shows Hemlibra Improves Quality of Life for Children with Hemophilia A
• 10/23/20 Study Finds Good Long Term Outcomes After Knee Replacements for Hemophilia Patients
• 10/12/20 NIH Awards$1.5M Grant to DNA Medicine Institute to Develop Rapid Fingerstick Test for Factor FVIII
• 10/7/20 First Participant Dosed in Phase 3 Study for Pfizer and Sangamo Gene Therapy
• 10/2/20 CSL Behring States Stimate Will Not Be Resupplied Until 2022
• 9/21/20 CSL Behring Will Discontinue Mononine for Hemophilia B
• 9/17/20 Genentech Provides Update on Particles in Hemlibra
• 9/17/20 Sanofi's BIVV001 Phase 1/2 Trial Results Show Promise
• 8/19/20 FDA Rejects BioMarin's Gene Therapy for Hemophilia A
• 7/22/20 CSL Behring and Ferring Have Issued a Recall of Stimate  
• 7/20/20 Data from Biopsy Study of BioMarin's Gene Therapy Shows Positive Results
• 7/20/20 Gene Therapy from BioMarin Could be the Most Expensive US Drug Ever
• 7/17/20 Phase 1/2 Trial of Gene Therapy for Hemophilia B Shows Promise
• 7/15/20 Data Shows Hemlibra Continues to Maintain a Favorable Safety Profile
• 7/13/20 Roche Posts Update on Hemophilia A Gene Therapy Data
• 6/3/20 Early Treatment Linked to Reduced Joint Damage in Young Adults with Severe Hemophilia A
• 5/13/20 BioMarin’s Gene Therapy for Hemophilia A Remains on Track for US Approval
• 5/4/20 Study Finds Prophylaxis is Better than On-Demand Treatment for Adults with Hemophilia A
• 5/1/20 NHF Adjust Annual Conference to Virtual Resource
• 4/15/20 New Bloodstream Media Podcast Tackles Pain
• 4/1/20 FDA Approves Sevenfact for Hemophilia A and B With Inhibitors
• 3/3/20 Medexus Acquires IXINITY from Aptevo
• 3/3/20 MASAC Addresses Concerns about Coronavirus and Bleeding Disorders
• 2/28/20 Survey of Healthcare Providers Shows Obesity a Likely Factor in Joint Bleeds
• 2/24/2020 Valrox, Gene Therapy for Hemophilia A, Accepted for Priority Review
• 2/10/2020 Novo Nordisk Launches Esperoct, Long-Acting Recombinant for Hemophilia
• 2/6/2020 Bloodstream Mini with Dr. Laura Fox, Physical Therapist
• 1/28/2020 FDA Updates Guidelines for Gene Therapy Treatments
• 1/24/2020 New Study Suggests Primary Postpartum Hemorrhage Remains a Challenge for Type 3 VWD Patients
• 1/20/2020 BioMarin Says Gene Therapy May Cost up to $3 Million
• 1/17/2020 Dr. Leonard A. Valentino chosen as the new President and CEO of NHF
• 1/8/2020 Sangamo Transfers Development of SB-525 Gene Therapy to Pfizer
• 12/23/2019 Dr. Christopher Ng Shares Research Update with “Ask The Expert” Podcast
• 12/10/2019 Emicizumab May Yield Improvements in Joint Health in Hemophilia Patients
• 12/10/2019 UniQure and Pfizer share updates on gene therapy trials for hemophilia B
• 12/9/2019 Takeda and Enzyre Partner to Develop Home Blood Test for Hemophilia Patients
• 12/8/2019 Study Presented at ASH Examines Adherence Rates for Hemophilia Patients Using Emicizumab
• 12/7/2019 Sangamo Shares Data for Gene Therapy Study on SB-525 for Hemophilia A
• 12/6/2019 New guidelines from MASAC on Bleeding Disorder Patients in the ER
• 11/25/2019 Paradigm Shift in Hemophilia Treatment, an Interview with Dr. Michael Wang
  
• 10/10/19 Application Deadline for NHF's National Youth Leadership Institute​ is Oct 31 
• 10/08/19 FDA Approves Wilate for Hemophilia A in Adult and Adolescent Patients 
• 10/07/19 Genentech Issues Statement on Hemlibra Particles; MASAC Responds 
• 9/13/19 Freeline's Gene Therapy for Hemophilia B Shows Promising Phase 1/2 Results 
• 9/10/19 Study Shows Hemophilia 3 Times as Prevalent in Men as Originally Thought 
• 9/10/19 BioMarin Explains Phase 3 Results for Hemophilia A Gene Therapy Trial 
• 9/9/19 Hemlibra Given with Immune Tolerance Induction Safely Treats Children 
• 8/28/19 FDA Grants Orphan Drug Designation to SIG-001 for Hemophilia A 
• 7/9/19 Positive Data from Multiple Studies Shared about Hemlibra at ISTH Congress 
• 7/8/19 New Results Presented on​ Catalyst's MarzAA for Hemophilia A or B 
• 7/8/19 BioMarin Announces Plans to Submit to FDA for Gene Therapy Marketing Authorization 
• 7/7/19 Bioverativ Presents Positive Data from Completed Phase 1/2 EXTEN-A Study 
• 7/6/19 Sangamo and Pfizer Announce Updated Phase 1/2 Results for Gene Therapy 
• 7/6/19 UniQure Announces Positive Follow Up Data from Gene Therapy Studies 
• 7/1/19 Study Finds Jivi May Protect Hemophilia A Patients Longer than Eloctate 
• 5/30/19 Six Ways for Young Adults to Make Adherence Easier 
• 5/29/19 Bayer Joins WFH to Help Hemophilia Patients in Developing Countries 
• 5/28/19 BioMarin Shares Data for Gene Therapy Before FDA Submission 
• 5/20/19 Being​ Fin's Mom: Life after your newborn has a stroke 
• 5/15/19 New Data for uniQure's Phase 2 Trial for AMT-061, Hemophilia B Gene Therapy 
• 5/9/19 Signs of Stroke in Babies and Toddlers 
• 5/8/19​ Talking About School Shootings 
• 5/1/19 Why We Can't Forget Children During Stroke Awareness Month 
• 4/23/19 Accumulator Program Update: Washington Tells Insurers "Not So Fast" 
• 4/17/19 Believe Limited Releases Soundtrack for Musical and Launches New Programs 
• 4/5/19 Catalyst Biosciences Enrolling for Phase 2b Trial for Hemophilia B Treatment 
• 4/2/19 NHF Joins PAN to Offer More Support for Bleeding Disorder Patients 
• 4/2/19 New Interim Data from Sangamo and Pfizer on Gene Therapy for Hemophilia A 
• 3/26/19 Study Finds Benefit from Extended Half-Life Products for Hemophilia A Patients 
• 3/25/19 Pharmacokinetic Dosing May Benefit Hemophilia A Patients Study Finds 
• 3/13/19 Precision BioLogic's Inhibitor Screening Kit Cleared by FDA for Sale in US 
• 2/25/19 Roche to Buy Spark Therapeutics for $4.3 Billion 
• 2/20/19 FDA Approves Novo Nordisk's Esperoct for Hemophilia A 
• 1/29/19 Pool More than a Safeguard for Sun Devil Swimmer Elijah Warren 
• 1/23/19 Study Finds Bleeding Tool Useful to Assess Hemophilia Severity 
• 1/21/19 Physical Therapists Rank Risks of Activities for Hemophilia Patients 
• 1/14/19 Non-Profit Save One Life Welcomes Chris Bombardier as New Executive Director 
• 1/11/19 Study Finds Hepatitis C a Major Predictor of Liver Cancer in Hemophilia Patients 
• 1/7/19 Phase 3 Study Shows Novoeight Safe and Effective Over Long Term 
• 12/17/18 Sangamo Treats 1st Patient in Trial of In Vivo Genome Editing for Hemophilia B 
• 12/3/18 Roche Shares Positive Data for Hemlibra at American Society of Hematology 
• 12/2/18 Data on Eloctate and Alprolix Show Efficacy and Safety over Four Years 
• 12/2/18 Spark Announces Updated Data for Gene Therapy SPK-8011 for Hemophilia A 
• 11/12/18 BioMarin Sponsors "Hemophilia:  The Musical" with Teens from Around the US 
• 11/7/18 Local Carson McCabe Interviewed on 9News After Being Chosen for Musical. 
• 10/29/18 Arvada Teen Performs in Musical about Bleeding Disorders in NYC 
• 10/24/18 Mimicry Not Replacement: Molecular Engineering Transforms Outlook 
• 10/23/18 AAV Gene Therapy Successfully Given Again to Dogs in Model of Hemophilia A 
• 10/23/18 NHF Publishes Review after 70th Annual Bleeding Disorders Conference 
• 10/4/18 FDA Approves Hemlibra for Hemophilia A Patients Without Inhibitors 
• 9/18/18 Many Watching FDA for Ruling on Subcutaneous Formulation of Hemlibra 
• 9/14/18 Liver Transplant Highly Benefits, but May Not Fully Cure, Hemophilia 
• 9/10/18 Study Finds More Hemophilia Patients are Overweight & Obese 
• 8/30/18 Genentech Shares Positive Phase III Results for Hemlibra in NEJM 
• 8/30/18 FDA Approves Jivi, a New Hemophilia Treatment 
• 8/16/18 Catalyst Provides Update on Phase 2/3 Trial for Hemophilia with Inhibitors 
• 8/13/18 They Thought Hemophilia was a "Lifelong Thing." They May Be Wrong 
• 8/8/18 Review Finds Multiple Factors Contribute to Inhibitors in Hemophilia 
• 8/8/18 Spark Updates Data for Hemophilia A Gene Therapy Trial 
• 7/30/18 Cost Analysis Compares Gene Therapy and Prophylaxis Care for Hemophilia A 
• 7/16/18 Pfizer Initiates Phase 3 Study for Hemophilia​ B Gene Therapy 
• 7/11/18 FDA Issues New Guidance for Advancing Gene Therapies, Including Hemophilia 
• 7/9/18 Study Finds Hemophilia Patients Still at Risk for Cardiovascular Disease 
• 7/2/18 NHF Collaborating with ASH, ISTH, and WFH to Create Guidelines on VWD Care 
• 6/28/18 UniQure Enrolls First Patient in Phase 3 HOPE-B Study​ of AMT-061 
• 6/18/18 Catalyst Biosciences Shares Update on CB2679 Program for Hemophilia B 
• 6/5/18 FDA Grants Priority Review to Emicizumab for Hemophilia A Without Inhibitors 
• 5/28/18 Octapharma Presents Data on Nuwiq for Hemophilia A Patients 
• 5/22/18 Spark and Pfizer Share Data from SPK-9001 Trial for Hemophilia B Patients 
• 5/22/18 FDA to Speed Path to Approval for Some Gene Therapies-Starting w/Hemophilia 
• 5/22/18 Data from Hemlibra Trials Shared at WFH World Congress 
• 5/21/18 Bioverativ Shares Data on BIVV001 for Hemophilia A Patients 
• 5/15/18 BioMarin Announces First Patient Dosed in Gene Therapy Study for Hemophilia A Patients with AAV5 Antibodies 
• 5/8/18 Takeda Secures Takeover of Shire with $62 Billion Deal 
• 4/30/18 Study Suggests Prophylaxis Could Reduce Hospitalizations for VWD Patients 
• 4/22/18 Sharon Funk Discusses PT and Bleeding Disorders in Ask the Expert Podcast 
• 4/17/18  FDA Grants Breakthrough Therapy Designation for Hemlibra 
• 3/26/18 Dr. Marilyn Manco-Johnson Talks Gene Therapy in Ask The Expert Podcast 
• 3/20/18 CSL Behring Discontinues Monoclate-P 
• 3/12/18 Sharon Funk and Lynn Magnuson Honored for Years of Service with CU Medicine 
• 3/5/18 Miracle of Hemophilia Drugs Comes at a Steep Price 
• 3/1/18 Blood Journal Article Indicates Hemophilia Gene Therapy is Effective and Safe 
• 3/1/18 NHF Helps Launch Campaign to Encourage Patients to Take Survey on HTC Care 
• 2/19/18 Barry Haarde, Hemophilia Advocate and Inspiration, Passes Away at 52 
• 2/17/18 Babies Who Suffer Stroke Regain Language Function in Opposite Side of
• 2/13/18 Hemophilia Gene Therapies Show Promise 
• 1/10/18 Catalyst Biosciences Given Permission to Change Trial Length for CB 2679d 
• 1/10/18 NY Times Shares Patient Voices: Hemophilia 
• 1/9/18 Alnylam and Sanofi Partner to Treat Rare Disorders 
• 1/6/18 Chris Bombardier Completes Seven Summits by Climbing Mt. Vinson 
• 12/11/17 BioMarin Shares New Data on Gene Therapy for Hemophilia A 
• 12/8/17 Gene Therapy Shows Promise for Hemophilia B 
• 12/5/17 Shire to Develop New Way to Administer Hemophilia Medications 
• 12/4/17 2017 NHF/Novo Nordisk Career Development Award Goes to Dr. Chris Ng 
• 11/21/17 Startup Could Bring Back Vioxx for Hemophilia Patients 
• 11/16/17 FDA Approves Hemlibra (Emicizumab) for Hemophilia A with Inhibitors 
• 11/9/17 Alnylam Announces Successful​ Outcome Following FDA Meeting on Fitusiran 
• 11/8/17 Hemophiliac Readies for Climb of Mt. Vinson, Final in 7 Summits 
• 11/6/17 Study Shows Positive Outcomes for Hemophilia A Patients 
• 10/30/17 FDA Accepts Beyer's Biologics License Application for BAY 94-9027 
• 10/27/17 FDA Grants BioMarin Investigational New Drug Status to BMN 270 
• 10/23/17 FDA Grants Orphan Drug Designation to Shire's SHP654 for Hemophilia A 
• 10/19/17 UniQure Announces New Study for Hemophilia B Gene Therapy Program 
• 10/9/17 Hemophilia A Study Shows Potential to Reduce Inhibitors 
• 10/2/17 BloodStream Podcast-Factor Revolution: 60 Years of Hemophilia 
• 9/28/17 How to Talk to Kids About Tragic Events 
• 9/28/17 NHF Collects Funds to Support Puerto Rico Patients with Bleeding Disorders 
• 9/28/17 Urgently Needed Hemophilia Drugs Delivered to Puerto Rico Pediatric Hospital 
• 9/26/17 Catalyst Biosciences Granted FDA Orphan Drug Designation for CB2679 
• 9/16/17 New Section of Memorial Dedicated to People w/Hemophilia who Died of AIDS 
• 9/11/17 "How do you thank someone for saving your life?" 
• 9/9/17 Bioverativ and Bicycle Join to Develop Drugs for Hemophilia 
• 9/7/17 Seven Ways You Can Prepare for Emergencies 
• 9/7/17 Alynlam's Hemophilia Program on Hold Following Patient Death 
• 9/6/17 Catalyst Biosciences Announces Positive Clinical Data for Hemophilia B Trial 
• 8/31/17 Bayer Submits BLA for Long-Acting Factor VIII for Hemophilia A 
• 8/24/17 Pfizer Launches Innovative Technologies for Hemophilia Patients 
• 8/24/17 FDA Grants Priority Review of Genentech's Emicizumab for Hemophilia A 
• 8/15/17 NHF, HFA and Hemophilia of Iowa File Hemophilia Discrimination Complaint 
• 7/20/17 Regis Jesuit's Elijah Warren Eager to Get Going at ASU 
• 7/14/17 Hemophilia B Pediatric, Adult Patients Benefit from Idelvion 
• 7/12/17 BioMarin, Spark, Raising the Stakes for Hemophilia 
• 7/11/17 BioMarin Announces Results from Study of BMN 270 to Treat Hemophilia A 
• 7/11/17 UniQure Presents Data on Hemophilia B Gene Therapy Research 
• 7/10/17 Promising New Data from Alnylam and Sanofi for Fitusiran 
• 7/6/17 NEJM Publishes Latest Update on HAVEN 1 Trail (Emicizumab) 
• 7/6/17 Shire Submits Application to FDA for Gene Therapy for Hemophilia A 
• 6/23/17 FDA Approves Bevyxxa to Prevent VTE in At-Risk Patients 
• 6/12/17 Man with Severe Hemophilia Talks about Climbing Mount Everest 
• 6/11/17 FDA Accepts Investigational New Drug Application for Hemophilia A Treatment 
• 6/1/17 Iowa Teen's $1 Million-Per-Month Illness No Longer a Secret 
• 5/31/17 FDA Approves Novo Nordisk's Rebinyn to Treat Hemophilia B 
• 5/22/17 Climber from Â鶹´«Ã½¸ßÇå with Hemophilia Summits Mt. Everest 
• 5/12/17 Sangamo and Pfizer to Collaborate on Hemophilia A Gene Therapy 
• 5/10/17 Dimension Therapeutics Discontinues Development of DTX101 
• 5/8/17 FDA Grants Orphan Drug, Fast Track to 2 Hemophilia Products 
• 5/2/17 Man from Â鶹´«Ã½¸ßÇå with Hemophilia is Making his way up Mt. Everest 
• 4/28/17 Children's Hospital Â鶹´«Ã½¸ßÇå Highlights Dr. Jorge DiPaola 
• 4/27/17 Prophylaxis Usage Analysis Authored by Dr. Marilyn Manco-Johnson Published 
• 4/18/17 Roche Reports Positive Results for Phase III HAVEN 2 Study 
• 4/17/17 Thousands Reach Out After Perth Woman's Bleeding Disorder Story 
• 4/17/17 CDC Updates Site on Preventing Inhibitors in Bleeding Disorders 
• 4/11/17 Catalyst Biosciences Reaches Milestone to Advance Factor IX Program 
• 3/31/17 Ryan White Letters to go on Display 
• 3/21/17 Amy Board of NHF CO and Chris Bombardier Interviewed on Â鶹´«Ã½¸ßÇå & Company 
• 3/15/17 Aptevo Therapeutics Announces New IXINITY Supply Available May 2017 
• 3/13/17 Washington Days Brings Big Crowd to Capitol Hill 
• 3/7/17 CU Anschutz Medical Campus Bus Shuttle a Transit Success 
• 3/2/17 "My Life, Our Future" Repository Opens Data to Researchers 
• 3/2/17 Chris Bombardier Takes on Mount Everest 
• 3/2/17 Data from Long Term Study of Alprolix to Treat Hemophilia B Published 
• 2/13/17 Plant Based Hemophilia Therapy Shows Promise to Reduce Inhibitors 
• 2/3/17 New Drugs to Treat Hepatitis C Under Priority Review at FDA 
• 1/30/17 uniQure's AMT-060 Gains Breakthrough Designation from FDA for Hemophilia B 
• 1/5/17 FDA Clears Sangamo's SB-525 Gene Therapy for Investigational New Drug 
• 12/31/16 NBC Checks Back in with Real Life Super Hero Kid "Iron Max" 
• 12/27/16 FDA Approves Adynovate to Treat Children and for Surgeries with Hemophilia A 
• 12/22/16 Roche's ACE-910 Succeeds in First of Three Final Stages of Clinical Trial 
• 12/20/16 Biogen Approves Spin-off Hemophilia Business Bioverativ 
• 12/6/16 NovoSeven Resolved 96.5% of Bleeds in Hemophilia A and B Patients 
• 12/5/16 Vonvendi, Treatment for von Willebrand Disease, Meets Endpoints in Study 
• 12/4/16 Alnylam Shares Positive Data on Fitusiran for Hemophilia Patients w/Inhibitors 
• 12/3/16 Biogen Presents Updated Data for Eloctate and Alprolix at ASH 
• 12/3/16 uniQure Announces Clinical Data from AMT-060 Phase I/II Trial 
• 12/3/16 CSL Behring Shares New Phase III Analysis of Idelvion for Hemophilia B 
• 12/3/16 Gene Transfer in Spark's Study Sustains Stable Factor Levels in Hemophilia B 
• 11/30/16 CRISPR Used for the First Time to Correct Hemophilia B in Mice 
• 11/28/16 UT Austin Develops First Capsule to Treat Hemophilia 
• 11/10/16 NHF Addresses Post-Election Questions on Affordable Care Act and Advocacy 
• 11/2/16 Adverse Events in Trial Dent Hopes for Roche Hemophilia Drug 
• 10/26/16 HFA Produces a Podcast Aimed at Young Adults with Hemophilia 
• 10/27/16 To Treat One Rare Blood Disorder, Scientists Exploit Another 
• 10/18/16 Prescription Benefit Program Changes for Recombinant Clotting Factor Product 
• 10/5/16 Virtual Reality Game Makes Infusions Easier on Young Patients 
• 10/4/16 FDA Warns of Risk of Hepatitis B Reactivating in Patients Treated for Hepatitis C 
• 9/28/16 Voices of 5000+ Patients: 1st National HTC Survey Experience Webinar 
• 9/16/16 New Method Identifies Female Carriers of Hemophilia A in Study 
• 9/11/16 Greeley Tribune Shares Ride the Rockies Experience of HTC Patient 
• 9/8/16 PPTA Updates News Release About Zika Virus and Blood Supply 
• 9/6/16 Sangamo BioSciences Receives Orphan Drug Status for SB-FIX 
• 8/30/16 National Hemophilia Foundation Videos Win National Awards  
• 8/22/16 Bloodstream Podcast Recaps NHF Annual Meeting and WFH World Congress 
• 8/15/16 Additional Lots of Kogenate FS Included in Voluntary Recall 
• 8/11/16 Extension of Voluntary Recall for Additional Lots of Helixate FS 
• 8/9/16 Vonvendi Now Available to Treat Adults with von Willebrand Disease 
• 8/9/16 Biogen Announces Hemophilia Spin-off Company as Bioverativ 
• 8/4/16 Bruising Uncommon in Very Young Children with Blood Disorders  
• 8/1/16 UniQure Shares Updated Clinical Data from Gene Therapy Trial of AMT-060 
• 7/29/16 Hemophilia Not Slowing Regis Jesuit Swim Star Warren 
• 7/29/16 Roche Reports Encouraging Data for Emicizumab at WFH Congress 
• 7/27/16 BioMarin Shares Dramatic Results from Gene Therapy Research 
• 7/27/16 Sangamo BioSciences Reveals New Gene Therapy Development Program 
• 7/27/16 CSL Behring Presents Data for Afstyla in Adolescents and Children 
• 7/26/16 Novo Nordisk Shares Data of Psychosocial Impact on People with Hemophilia B 
• 7/26/16 CSL Behring Presents Phase III Data for Idelvion to Treat Hemophilia B 
• 7/25/16 Alnylam Pharma Announces Positive Data for Fitusiran Phase I Study 
• 7/25/16 CSL Behring Announces Voluntary Recall of Two lots of Helixate FS 
• 7/25/16 Bayer Announces Voluntary Recall of Two Lots of Kogenate FS 
• 7/21/16 Spark Therapeutics and Pfizer Gain FDA Breakthrough Designation for SPK-9001 
• 7/8/16 Kovate DVI Shipments on Hold 
• 6/28/16 SIPPET Study & MASAC Recommendations Explained 
• 6/28/16 FDA Approves Epclusa to Treat Hepatitis C 
• 6/22/16 New Podcast for Bleeding Disorders Launches 
• 6/16/16 Analysis Published in Blood Reviews Outcomes 
• 6/14/16 Drug Makers Work to Woo Kids with Hemophilia 
• 6/13/16 Spark Therapeutics Releases Positive Data on Gene Therapy 
• 6/13/16 UniQure Presents Data from Gene Therapy Trail for Hemophilia B 
• 5/28/16 FDA Approves CSL Behring's Afstyla to Treat Hemophilia A 
• 5/26/16 SIPPET Study Results Published in New England Journal of Medicine 
• 5/13/16 CSL Behring's Idevlion Receives Marketing Exclusivity from FDA 
• 5/9/16 US Health Officials Brace for Battle with Zika 
• 5/3/16 Biogen Announces Intent to Spin off its Hemophilia Business 
• 4/22/16 Dept of Health & Human Services Supports Study of Zika Blood Screening Test 
• 4/20/16 BioMarin Provides Encouraging Update in Hemophilia A Gene Therapy Program 
• 4/16/16 Woman Fights for Females Living with Bleeding Disorders 
• 4/14/16 Biogen Joins in Celebration of World Hemophilia Day 
• 4/13/16 CSL Behring Marks World Hemophilia Day by Donating Medications 
• 3/28/16 Research on Mice Shows Concurrent Influenza Vaccination Reduces Inhibitors 
• 3/20/16 Youth is Served in Stroke Save 
• 3/16/16 Study of Hemophilia Care Reveals Progress, Ongoing Health Needs 
• 3/7/16 FDA Approves Idelvion to Treat Hemophilia B 
• 3/1/16 Dr. Holbrook Khort, Hemophiliac Who Made Condition a Crusade, Dies at 38 
• 3/1/16 BioMarin Receives Orphan Drug Status from FDA for First AAV-Factor VIII Gene Therapy, BMN 270, to Treat Hemophilia A 
• 2/27/16 Baxalta Submits sBLA for Adynovate to Treat Pediatric Hemophilia A Patients 
• 2/4/16 NHF Provides Updates on Actions Being Taken to Keep Blood Supply Safe 
• 2/4/16 WFH Releases Statement on Zika Virus and Plasma Derived Treatment Products 
• 2/4/16 HFA Provides Updates and Info on Zika Virus and the Blood Supply 
• 2/3/16 Red Cross Takes Steps to Prevent Zika Virus in Blood Supply 
• 1/28/16 FDA Approves Zepatier to Treat Chronic Hepatitis C Genotypes 1 and 4 
• 1/27/16 Gilead Faces Scrutiny, Lawsuits Over Pricing of Treatments for AIDS/Hep C 
• 1/27/16 March Officially Named Bleeding Disorders Awareness Month 
• 1/20/16 Gene Therapy Research Shows Potential for Long Lasting Treatment 
• 1/13/16 Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary 
• 1/11/16 Drug Maker Shire to Buy Baxalta for $32 Billion 
• 1/6/16 Gilead Snags Priority Review for Pangenotype Hepatitis C Combo Treatment 
• 1/4/16 Octapharma's NUWIQ Now Available in the US to Treat Hemophilia A 
• 12/21/15 Sernova Awarded Grant to Fund Development of Cell-Based Treatment for Hemophilia A 
• 12/17/15 SIPPET Results Presented at ASH 2015 
• 12/16/15 Arsia & Biogen Unite to Develop Subcutaneous Method for Delivering Hemophilia Medications 
• 12/08/15 FDA Approves Vonvendi as First Recombinant von Willebrand Factor Treatment 
• 12/08/15 New Data Shows Eloctate & Alprolix May Manage Target Joint Bleeds and Maintain Low Annual Bleeding Rates for Severe Hemophilia A & B 
• 12/07/15 NHF CO Selects Denver Brandworks to Expand "Backpacks & Bleeders" Program 
• 12/07/15 Positive Data for Alnylam's Once-Monthly Fitusiran (ALN-AT3) to Treat Hemophilia A & B 
• 12/07/15 New Data Presented by Sangamo BioSciences on SB-FIX, Clotting Protein  to Treat Hemophilia B 
• 12/07/15 Baxalta Shares Updates on Trial of ADYNOVATE to treat Hemophilia A 
• 12/07/15 CSL Behring Presents Data From Phase III Trial for Long Acting rIX-FP to Treat Hemophilia B 
• 12/02/15 FDA Accepts New Drug Application for AbbVie's Once-a-day VIEKIRA PAK to Treat Hepatitis C Genotype 1 
• 12/01/15 FDA Clears Investigational New Drug Application by Sangamo BioSciences for SB-FIX to Treat Hemophilia B 
• 12/01/15 Study of ACE910 Suggests Treatment May Result in Fewer Injections to Treat Hemophilia A 
• 11/13/15 FDA Approves Adynovate for Hemophilia A 
• 11/2/15 BDI Pharma, Inc. Selected as Authorized Distributor of Coagadex 
• 11/2/15 Research at Rice University Yields New Answers about Factor VIII 
• 10/20/15 FDA Approves First Factor X Concentrate to Treat Patients with Bleeding Disorder 
• 10/19/15 Lettuce Can Make Drugs That Don't Require Refrigeration 
• 10/8/15 Alnylam Pharma Announces Phase 1 Study with ALN-AT3 to Treat Bleeding Disorders 
• 10/8/15 Octapharma Licenses Glycotope Platform; Takes Stake in Company 
• 10/2/15 Infections May Temporarily Increase Children's Stroke Risk 
• 9/30/15 New Hepatitis C Combination Shows Positive Results Across All Genotypes 
• 9/28/15 BioMarin Enrolls Patients in Gene Therapy Trial for BMN 270 to Treat Hemophilia A 
• 9/28/15 NHF Announces Comprehensive Care Sustainability Collaborative (CCSC) 
• 9/17/15 FDA Grants Fast Track Designation for Dimension's DTX101 to Treat Hemophilia B  
• 9/16/15 FDA Approves Octapharma's NUWIQ to Treat Hemophilia A 
• 9/10/15 FDA Accepts Dimension's DTX101 as Investigational New Drug and Grants Orphan Designation to Treat Hemophilia B 
• 9/4/15 FDA Grants Breakthrough Therapy Designation to Genentech's ACE910 to Treat Hemophilia A with Factor VIII Inhibitors 
• 9/3/15 World Leaders Meet at First World Hepatitis Summit to Discuss Prevention 
• 9/1/15 Recombinant FVIII with Extended Half-Life Shown Safe, Effective for Hemophilia A 
• 8/26/15 CSL Behring Enrolling for Study of rVIIa-FP for Hemophilia Patients with Inhibitors 
• 8/17/15 Biogen Issues Positive Update on Alprolix Phase III Study for Hemophilia B 
• 8/10/15 Data Supporting Long-Term Safety of Eloctate Published in Haemophilia 
• 8/3/15 Hemophilia Drugs a Big Part of Medicaid Spending 
• 8/3/15 Engineered Clotting Protein Effective in Severe von Willebrand Disease 
• 7/28/15 FDA Publishes Drug Shortage Ruling 
• 7/28/15 FDA Accepts CSL Behring's BLA for Hemophilia Therapy 
• 7/24/15 Bristol-Myers, AbbVie get FDA Approval for Hepatitis C Treatments 
• 7/24/15 FDA Approves Technivie for Treatment of Chronic Hepatitis C Genotype 4 
• 7/24/15 Researchers Find Way to Reverse Clotting Factor Deficiency Triggering Hemophilia A 
• 7/12/15 CU Doctor Earns Awards to Research Improving Hemophilia Outcomes 
• 7/11/15 Hepatitis Drug Overtakes $1000-per-pill Treatment in Shifting Options for Care 
• 7/1/150 Baxalta Launches as Spinoff of Baxter Aimed at Underserved Conditions 
• 7/1/15 Bayer Files Hemophilia A Drug Marketing Application in Japan 
• 6/29/15 Walgreen Settles Medicaid False Billing Case in New York 
• 6/25/2015 Data Shown on the Impacts of Hemophilia on Caregivers and Patients 
• 6/25/2015 CSL Behring Presents Data from Phase I/III rVIII Single-Chain Study 
• 6/24/2015 Novo Nordisk Presents Positive Data for the Treatment of Hemophilia A 
• 6/24/2015 Baxalta Provides Update on Progress with Hemophilia B Gene Therapy 
• 6/24/2015 Catalyst Announces Results from Phase I Trial to Treat Hemophilia 
• 6/24/2015 CSL Behring Presents rIX-FP Data for Phase III trial for Hemophilia B 
• 6/24/2015 Alnylam Reports Data for ALN-AT3 for Treatment of Hemophilia A & B 
• 6/19/2015 Quick Action Saves Teen from Stroke 
• 6/10/2015 Apitope's Inhibitor Drug ATX-F8-117 Granted Orphan Drug Status 
• 6/2/2015 Mountaineer and Hemophiliac Chris Bombardier to Conquer Highest Summit on Each Continent 
• 4/30/2015 FDA Approves IXINITY from Emergent BioSolutions to Treat Hemophilia B 
• 4/28/2015 Merck's Grazoprevir/Elbasvir Combo cures 99% of Hep C Patients with Chronic Kidney Disease 
• 4/20/2015 Baxter Submits Positive Data for BAX111 to Treat von Willebrand Disease 
• 4/14/2015 CSL Behring Renews Pledge to World Federation of Hemophilia 
• 4/13/2015 Employees & Patients Find Joy in Giving back to the Hemophilia Community 
• 4/13/2015 RNAi Therapy Targets Antithrombin to Promote Clotting for Hemophilia A & B 
• 3/26/2015 Novo Nordisk Announces US Launch of Novoeight for Hemophilia A 
• 3/24/2015 FDA Warns of Serious Drug Interaction with Hep C Drugs Harvoni & Sovaldi 
• 3/20/2015 New Study Finds Hemophilia Carriers Have Evidence of Joint Abnormalities 
• 3/12/2015 One Time Dose of Gene Therapy in Animal Testing Treats Hemophilia B 
• 3/12/2015 Study Uses Gene Therapy to Produce Mutated Protein as Tool for Hemophilia 
• 3/4/2015 FDA Accepts Bayer's Biologics License Application for BAY 81-8973 to Treat Hemophilia A in Children and Adults 
• 2/27/2015 Biogen Idec & Sobi Report Positive Results from Phase III Alprolix Pediatric Study

• 2/25/2015 Acquired Hemophilia A Successfully Treated with Rituximab & 
• 2/4/2015 FDA Accepts Review for CSL Behring's BLA for rIX-FP for Hemophilia B 
• 1/30/2015 OPKO Submits to Initiate Phase 2a Trial for Long Acting Coagulation Factor VIIa-CTP to treat Hemophilia 
• 1/29/2015 Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Collaboration to Develop Gene Therapies for Hemophilia 
• 12/24/2014 Baxter seeks FDA Approval for BAX111 to treat Von Willebrand Disease 
• 10/24/2014 FDA Approves Obizur for Treatment of Acquired Hemophilia A 
• 10/01/2014 World Thrombosis Day is October 13 
• 9/24/2014 NSAIDS Linked to Increased Venous Thromboembolism Risk 
• 7/17/2014 Plant Based Research Improves Hemophilia Treatment 
• 7/16/2014 Pfizer Hemophilia B Treatment Meets Endpoint in Phase 3 Trial 
• 7/2/2014 Dr. Bernard Discusses Pediatric Stroke on Â鶹´«Ã½¸ßÇå Public Radio 
• 6/30/2014 NF and McMaster Univ. Collaborate on Guidelines for HTCs 
• 6/6/2014 FDA Approves Longer-Lasting Eloctate for Treatment of Hemophilia A 
• 6/6/2014 European Commission Approves Pradaxa for Prevention of DVT and PE 
• 5/20/2014 University of Â鶹´«Ã½¸ßÇå HTC joined , please follow us!
• 5/18/2014 Drug Companies Pledge Factor VIII Donation in Developing Countries 
• 5/18/2014 CU Gets Grant to Study Pediatric Strokes 
• 5/16/2014 University of Â鶹´«Ã½¸ßÇå HTC joined , please like our page!
• 5/12/2014 New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP) 
• 5/12/2014 FDA Approves Bayer's Kogenate FS Antihemophilic Factor VIII (recombinant) for Routine Prophylaxis in Adults with Hemophilia A 
• 4/23/2014 Baxter Announces FDA Approval of ADVATE with BAXJECT III Reconstitution System 
• 4/10/2014 88% of Previous Relapsers Achieve Hepatitis C Cure with Simeprevir-based Triple Therapy 
• 4/9/2014 Boehringer's Pradaxa Gets FDA Approval for DVT, PE Treatment 
• 4/2/2014 Baxter Acquires Chatham for $70M+, Boosting it's Hemophilia Pipeline 
• 3/28/2014 U.S. FDA approves Biogen's Hemophilia drug Alprolix 
• 3/22/2014 Canada OKs Biogen Idec Drug for Treatment of Hemophilia B 
• 3/13/2014 Stroke in Children Will be Focus of $3 M Grant at CU 
• 3/7/2014 New Hemophilia Drugs Aim to Simplify Treatment 
• ​3/1/14 March is Hemophilia Awareness Month. Find free downloads for Facebook to support those with bleeding disorders, and get the facts about Hemophilia and other bleeding disorders.    
• 3/1/14 March is Blood Clot and Deep Vein Thrombosis Awareness Month. Find out more about DVT and blood clots and what you can do to prevent them, especially if you or your family have genetic predisposition to clots.   
• 2/12/14 Common infections linked to stroke in children; vaccines may reduce risk